BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 9, 2015
View Archived Issues
Cationically modified dextran heparin antidotes show promise in vivo
Read More
FDA designates ataluren an orphan drug for aniridia
Read More
Shionogi terminates agreement with OncoTherapy Science for peptide vaccine in the ophthalmic field
Read More
Juno Therapeutics begins phase II trial of JCAR-015
Read More
Batu Biologics begins discovery research in Immittam program
Read More
Updated efficacy data reported for L-DOS-47 in NSCLC
Read More
Autifony Therapeutics K+ channel modulator improves cognition in schizophrenia model
Read More
Mitochondrial DNA mutation linked to mitochondrial hepatopathy
Read More
Relaxin levels linked to risk of death in patients with acute heart failure
Read More
Strongbridge Biopharma is the new name for Cortendo
Read More
Promedior begins phase II study of PRM-151 in IPF
Read More
Achillion discloses complement factor D inhibitors
Read More
AstraZeneca and University of Manchester launch clinical bioinformatics collaboration
Read More
Acetylon presents HDAC6 inhibitors
Read More
Piramal patents multikinase inhibitors
Read More
Shanghai Haiyan discovers new EFGR inhibitors
Read More
Biodim presents bacterial dltA inhibitors
Read More
Serendex receives German clearance to initiate phase II trial of molgramostim
Read More
Oryzon completes multiple ascending dose portion of phase I trial of ORY-1001
Read More
Akebia reports results from phase II trial of vadadustat in CKD-related anemia
Read More
Biogen in-licenses Mitsubishi Tanabe's MT-1303 for autoimmune diseases
Read More
Topline phase II data on GKT-137831 support development in fibrotic diseases
Read More
Topline results from phase III IGNITE2 study of eravacycline for cUTI
Read More
Single oral doses of Vitae's VTP-43742 safe in healthy volunteers
Read More
Five Prime starts dosing in phase I trial of FPA-008 and nivolumab
Read More
FDA grants priority review to alectinib NDA for ALK-positive NSCLC
Read More